

Jeff Gershenwald

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9345304/jeff-gershenwald-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

318
papers

39,060
citations

85
h-index

195
g-index

374
ext. papers

47,242
ext. citations

11.1
avg, IF

6.74
L-index

#	Paper	IF	Citations
3 ¹⁸	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	1
3 ¹⁷	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	2
3 ¹⁶	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 200	8.5	
3 ¹⁵	Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts.. <i>Annals of Surgical Oncology</i> , 2022 ,	3.1	2
3 ¹⁴	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. <i>Science</i> , 2021 , 374, 1632-1640	33.3	52
3 ¹³	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in -mutated melanoma. <i>Oncotarget</i> , 2021 , 10, 1992880	7.2	2
3 ¹²	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. <i>Scientific Reports</i> , 2021 , 11, 9043	4.9	2
3 ¹¹	A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences. <i>British Journal of Dermatology</i> , 2021 , 185, 101-109	4	4
3 ¹⁰	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021 , 28, 3480-3489	3.1	1
3 ⁰⁹	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021 , 19, 142	8.5	1
3 ⁰⁸	Be Well Communities—mobilizing communities to promote wellness and stop cancer before it starts. <i>Cancer Causes and Control</i> , 2021 , 32, 859-870	2.8	1
3 ⁰⁷	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021 , 27, 1432-1441	50.5	57
3 ⁰⁶	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021 , 27, 2678-2697	12.9	11
3 ⁰⁵	Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management. <i>Archives of Pathology and Laboratory Medicine</i> , 2021 , 145, 1505-1515	5	1
3 ⁰⁴	Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. <i>Surgical Oncology</i> , 2020 , 34, 182-185	2.5	13
3 ⁰³	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2719-2727	2.2	29
3 ⁰²	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 875-885	9.7	7

301	FOX D3 Regulates VISTA Expression in Melanoma. <i>Cell Reports</i> , 2020 , 30, 510-524.e6	10.6	17
300	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020 , 577, 549-555	50.4	654
299	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1429-1441	2.2	9
298	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 1886-1895	12.9	24
297	Melanoma Prognosis and Staging 2020 , 271-297		1
296	Models for Predicting Melanoma Outcome 2020 , 299-314		
295	Melanoma Prevention and Screening 2020 , 525-570		1
294	Functional annotation of melanoma risk loci identifies novel susceptibility genes. <i>Carcinogenesis</i> , 2020 , 41, 452-457	4.6	2
293	Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. <i>Cancer</i> , 2020 , 126, 775-781	6.4	5
292	Melanoma pathology reporting and staging. <i>Modern Pathology</i> , 2020 , 33, 15-24	9.8	34
291	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020 , 16, 4429-4438	3.6	23
290	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020 , 31, 1569-1579	10.3	8
289	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020 , 9, 8650-8661	4.8	3
288	Virtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations. <i>Annals of Surgery</i> , 2020 , 272, e144-e147	7.8	32
287	Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. <i>JAMA Dermatology</i> , 2020 , 156, 1004-1011	5.1	24
286	Updates in the evidence-based management of cutaneous melanoma. <i>Head and Neck</i> , 2020 , 42, 3396-3404	4.4	0
285	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020 , 33, 496-513	9.8	9
284	The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , 2020 , 18, 171	8.5	1

283	Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 2352-2358.e15	4.3	15
282	Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2667-2674	3.1	2
281	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1314-1322	9.7	17
280	Telementoring and smartphone-based answering systems to optimize dermatology resident dermoscopy education. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, e27-e28	4.5	4
279	Melanoma Clinical Staging (Historical and Current) 2019 , 485-500		
278	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , 2019 , 20, e378-e389	21.7	88
277	Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9543-9543	2.2	1
276	Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9596-TPS9596	2.2	3
275	Melanoma Prevention and Screening 2019 , 1-46		1
274	Models for Predicting Melanoma Outcome 2019 , 1-16		
273	Melanoma Prognosis and Staging 2019 , 1-27		
272	Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS145-TPS145	2.2	
271	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019 , 9, 628-645	24.4	124
270	Enhancing Case Capture, Quality, and Completeness of Primary Melanoma Pathology Records via Natural Language Processing. <i>JCO Clinical Cancer Informatics</i> , 2019 , 3, 1-11	5.2	3
269	Isolated Immunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 1442-1444	6.7	3
268	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 7585-7593	12.9	12
267	Guidelines of care for the management of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 208-250	4.5	202
266	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019 , 125, 18-44	6.4	15

265	Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2172-2177	3.1	10
264	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 181-193	21.7	168
263	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology, The</i> , 2018 , 19, 310-322	21.7	284
262	The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. <i>Journal of Translational Medicine</i> , 2018 , 16, 101	8.5	3
261	Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. <i>Cancer Medicine</i> , 2018 , 7, 583-593	4.8	25
260	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018 , 359, 97-103	33.3	1895
259	ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. <i>Cancer Research</i> , 2018 , 78, 5680-5693	10.1	12
258	Staging and Classification of Melanoma 2018 , 87-103		
257	Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. <i>American Journal of Dermatopathology</i> , 2018 , 40, 831-835	0.9	
256	Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application 2018 ,		3
255	Stage at presentation to determine associations between histologic parameters of primary tumor and disease specific survival (DSS) in anorectal melanoma (AM).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21622-e21622	2.2	
254	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 775-784	3.5	81
253	Melanoma Clinical Staging (Historical and Current) 2018 , 1-16		
252	Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	13
251	Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 88-100	7.1	15
250	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018 , 24, 1649-1654	50.5	377
249	A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. <i>Journal of Surgical Oncology</i> , 2018 , 118, 922-927	2.8	8
248	Staging of Cutaneous Melanoma: Is There Room for Further Improvement?. <i>JAMA Network Open</i> , 2018 , 1, e180086	10.4	2

247	Role of Elevated Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2018 , 24, 4119-4125	12.9	5
246	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018 , 24, 4416-4428	12.9	58
245	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018 , 29, 1861-1868	10.3	77
244	The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. <i>Ca-A Cancer Journal for Clinicians</i> , 2017 , 67, 93-99	220.7	1819
243	Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. <i>Surgery</i> , 2017 , 161, 1246-1254	3.6	14
242	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	409
241	Skin Cancer: Have melanoma and skin cancer finally met their match?. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 267-268	19.4	2
240	Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1792-1795	4.3	26
239	Clinicopathological features and clinical outcomes associated with TP53 and BRAF mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017 , 123, 1372-1381	6.4	28
238	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017 , 376, 2211-2222	59.2	739
237	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017 , 2,	6.2	82
236	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. <i>Clinical Cancer Research</i> , 2017 , 23, 2093-2104	12.9	37
235	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017 , 67, 472-492	220.7	1044
234	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , 2017 , 32, 204-220.e15	24.3	391
233	Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. <i>JAMA Dermatology</i> , 2017 , 153, 228-229	5.1	10
232	Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 253-257	4.3	2
231	Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome 2017 ,		3
230	Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3008-3008	2.2	17

229	Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9579-9579	2.2	3
228	A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9582-9582	2.2	6
227	Relapse-free survival and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9587-9587	2.2	3
226	Principles of Cancer Staging 2017 , 3-30		26
225	Organization of the AJCC Cancer Staging Manual 2017 , 31-37		115
224	Risk Models for Individualized Prognosis in the Practice of Precision Oncology 2017 , 47-52		0
223	Melanoma of the Skin 2017 , 563-586		58
222	State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 460-480	220.7	93
221	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016 , 14, 168	11.4	87
220	Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1913-1914	27.4	4
219	Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	114
218	4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. <i>Melanoma Research</i> , 2016 , 26, 181-7	3.3	4
217	Correlates of Sun Protection and Sunburn in Children of Melanoma Survivors. <i>American Journal of Preventive Medicine</i> , 2016 , 51, e77-85	6.1	14
216	Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US Surveillance, Epidemiology, and End Results, 2005-2011). <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1894-1897	4.3	6
215	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016 , 6, 827-37	24.4	561
214	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016 , 6, 202-16	24.4	841
213	Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1741-7	2.2	49
212	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Onc Immunology</i> , 2016 , 5, e1136044	7.2	42

211	Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016 , 22, 3016-24	12.9	31
210	Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1079-86	2.2	58
209	Principles of Melanoma Staging. <i>Cancer Treatment and Research</i> , 2016 , 167, 131-48	3.5	23
208	Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy 2016 ,		9
207	A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9594-TPS9594	2.2	2
206	Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFNon-V600 (NonV600) mutations (mut).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9535-9535	2.2	
205	CDC Grand Rounds: Prevention and Control of Skin Cancer. <i>American Journal of Transplantation</i> , 2016 , 16, 717-720	8.7	4
204	Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. <i>Medicine (United States)</i> , 2016 , 95, e3073	1.8	28
203	Critical Assessment of Clinical Prognostic Tools in Melanoma. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2753-61	3.6	36
202	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 404-16	4.5	63
201	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 370-4	220.7	219
200	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015 , 161, 1681-96	56.2	1807
199	Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2266-2272	4.3	5
198	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15003	51.1	283
197	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015 , 46, 1101-10	3.7	33
196	Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 508-515	4.3	99
195	The relationship between blood IL-12p40 level and melanoma progression. <i>International Journal of Cancer</i> , 2015 , 136, 1874-80	7.5	2
194	Improving the quality of cancer staging. <i>Ca-A Cancer Journal for Clinicians</i> , 2015 , 65, 261-3	220.7	20

193	Biology of advanced uveal melanoma and next steps for clinical therapeutics. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 135-47	4.5	62
192	Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. <i>European Journal of Cancer Care</i> , 2015 , 24, 724-33	2.4	26
191	Enforcement Provisions of Indoor Tanning Bans for Minors: An Analysis of the First 6 US States. <i>American Journal of Public Health</i> , 2015 , 105, e10-2	5.1	8
190	The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. <i>Journal of Surgical Oncology</i> , 2015 , 112, 834-40	2.8	18
189	Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 2521-6	11.5	13
188	C-reactive protein as a marker of melanoma progression. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1389-96	2.2	55
187	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. <i>Nature Cell Biology</i> , 2015 , 17, 311-21	23.4	155
186	CDC Grand Rounds: Prevention and Control of Skin Cancer. <i>Morbidity and Mortality Weekly Report</i> , 2015 , 64, 1312-4	31.7	9
185	Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. <i>Annals of Surgical Oncology</i> , 2014 , 21, 1075-81	3.1	101
184	Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. <i>Clinical Cancer Research</i> , 2014 , 20, 5527-36	12.9	103
183	Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 637-643	4.5	92
182	Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. <i>Annals of Surgery</i> , 2014 , 259, 1215-22	7.8	35
181	Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 452-460	4.3	14
180	Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6,908 cases from the National Cancer Data Base.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9014-9014	2.2	4
179	A highly recurrent RPS27 5'UTR mutation in melanoma. <i>Oncotarget</i> , 2014 , 5, 2912-7	3.3	45
178	Tissue resources for clinical use and marker studies in melanoma. <i>Methods in Molecular Biology</i> , 2014 , 1102, 679-95	1.4	6
177	Do patient-reported quality-of-life responses in melanoma patients vary by stage?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20007-e20007	2.2	
176	Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013 , 119, 3821-9	6.4	79

175	Age as a prognostic factor in patients with localized melanoma and regional metastases. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3961-8	3.1	118
174	Semiconductor-based DNA sequencing of histone modification states. <i>Nature Communications</i> , 2013 , 4, 2672	17.4	13
173	Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 13481-6	11.5	127
172	Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience. <i>Clinics in Dermatology</i> , 2013 , 31, 298-310	3	20
171	Polymorphisms of nucleotide excision repair genes predict melanoma survival. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1813-21	4.3	39
170	Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). <i>Clinical Cancer Research</i> , 2013 , 19, 3611-20	12.9	31
169	Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. <i>Melanoma Research</i> , 2013 , 23, 290-7	3.3	36
168	Randomized controlled trial of a sun protection intervention for children of melanoma survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1813-24	4	18
167	Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. <i>BioMed Research International</i> , 2013 , 2013, 898719	3	12
166	Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. <i>Pigment Cell and Melanoma Research</i> , 2013 , 26, 422-5	4.5	4
165	Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 ,	7.1	13
164	Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e320-e325	7.1	1
163	Cutaneous Melanoma 2013 , 153-165		1
162	A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. <i>Journal of the American College of Surgeons</i> , 2012 , 214, 608-17; discussion 617-9	4.4	24
161	Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. <i>Clinical Cancer Research</i> , 2012 , 18, 6758-70	12.9	291
160	Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. <i>American Journal of Pathology</i> , 2012 , 180, 2170-81	5.8	27
159	A landscape of driver mutations in melanoma. <i>Cell</i> , 2012 , 150, 251-63	56.2	1799
158	NRAS mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012 , 118, 4014-23	6.4	483

157	Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. <i>Melanoma Research</i> , 2012 , 22, 376-85	3.3	37
156	Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. <i>Melanoma Research</i> , 2012 , 22, 169-75	3.3	13
155	Sentinel lymph node biopsy in melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 185-91	2.2	25
154	Impact of comorbidities on overall survival of high-risk and advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8536-8536	2.2	1
153	The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. <i>Oncotarget</i> , 2012 , 3, 336-44	3.3	19
152	A lupus-like reaction to subcutaneous interferon- β injection sites. <i>Journal of Drugs in Dermatology</i> , 2012 , 11, 393-8	2.2	2
151	Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary. <i>Surgical Oncology Clinics of North America</i> , 2011 , 20, 57-78	2.7	17
150	Targeted therapy for melanoma: a primer. <i>Surgical Oncology Clinics of North America</i> , 2011 , 20, 165-80	2.7	19
149	Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. <i>Value in Health</i> , 2011 , 14, 900-6	3.3	36
148	Sentinel-lymph-node biopsy for cutaneous melanoma. <i>New England Journal of Medicine</i> , 2011 , 364, 1738-45	5.2	104
147	Staging and prognosis of cutaneous melanoma. <i>Surgical Oncology Clinics of North America</i> , 2011 , 20, 1-17	2.7	115
146	Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. <i>Clinical Radiology</i> , 2011 , 66, 224-36	2.9	43
145	Promoter polymorphisms in matrix metalloproteinase 1 and risk of cutaneous melanoma. <i>European Journal of Cancer</i> , 2011 , 47, 107-15	7.5	10
144	Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. <i>Annals of Surgery</i> , 2011 , 253, 1211-5	7.8	65
143	Exome sequencing identifies GRIN2A as frequently mutated in melanoma. <i>Nature Genetics</i> , 2011 , 43, 442-6	36.3	385
142	Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3593-600	3.1	68
141	Lymphangiogenesis and hemangiogenesis: potential targets for therapy. <i>Journal of Surgical Oncology</i> , 2011 , 103, 489-500	2.8	30
140	Cutaneous melanoma: a model to study cancer metastasis. <i>Journal of Surgical Oncology</i> , 2011 , 103, 538-49	2.7	27

139	Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. <i>Journal of Surgical Oncology</i> , 2011 , 104, 379-85	2.8	102
138	Evidence-based treatment of early-stage melanoma. <i>Journal of Surgical Oncology</i> , 2011 , 104, 341-53	2.8	41
137	Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. <i>Human Molecular Genetics</i> , 2011 , 20, 5012-23	5.6	164
136	Clinical correlates of NRAS and BRAF mutations in primary human melanoma. <i>Clinical Cancer Research</i> , 2011 , 17, 229-35	12.9	206
135	Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 129-42	9.7	219
134	Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. <i>Clinical Cancer Research</i> , 2011 , 17, 4882-91	12.9	43
133	Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2199-205	2.2	250
132	Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 18637-42	11.5	60
131	Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. <i>Nature Genetics</i> , 2011 , 43, 1119-26	36.3	116
130	Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 8500-8500	2.2	10
129	Prognostic Factors and Staging in Melanoma 2011 , 282-294		
128	Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2452-9	2.2	320
127	Reply to J.M. Thomas et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e480-e481	2.2	1
126	Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. <i>Molecular Cancer Research</i> , 2010 , 8, 1513-25	6.6	41
125	Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 751-61	4.5	409
124	Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. <i>Neoplasia</i> , 2010 , 12, 173-82	6.4	40
123	Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. <i>Annals of Surgical Oncology</i> , 2010 , 17, 709-17	3.1	84
122	Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2764-72	3.1	112

121	Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2006-14	3.1	87
120	Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2015-23	3.1	25
119	Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. <i>Cancer</i> , 2010 , 116, 2234-41	6.4	66
118	Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 8516-8516	2.2	4
117	Diagnostic imaging modalities for the surveillance of melanoma patients: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 8581-8581	2.2	2
116	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2009 , 15, 7538-7546	12.9	184
115	Lymph node ratio predicts disease-specific survival in melanoma patients. <i>Cancer</i> , 2009 , 115, 2505-13	6.4	51
114	Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. <i>Journal of Cutaneous Pathology</i> , 2009 , 36, 1157-63	1.7	66
113	Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 73, 1376-82	4	32
112	Final version of 2009 AJCC melanoma staging and classification. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6199-206	2.2	3512
111	Sentinel node biopsy and standard of care for melanoma. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 872-5	4.5	107
110	CpG island methylation profiling in human melanoma cell lines. <i>Melanoma Research</i> , 2009 , 19, 146-55	3.3	79
109	Role of sentinel lymph node biopsy in patients with thin melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 308-17	7.3	81
108	A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. <i>Melanoma Research</i> , 2009 , 19, 42-9	3.3	33
107	Therapeutic Targeting of the Lymphovascular System in Cancer: Promise and Challenge 2009 , 191-199		
106	Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3021-3021	2.2	
105	Quantitative assessment of AKT activation in melanoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 9022-9022		
104	Phase II trial of imatinib mesylate in patients with metastatic melanoma. <i>British Journal of Cancer</i> , 2008 , 99, 734-40	8.7	181

103	A novel AKT3 mutation in melanoma tumours and cell lines. <i>British Journal of Cancer</i> , 2008 , 99, 1265-8	8.7	214
102	Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1585-8	4.3	24
101	Fellowship training in surgical oncology--an international affair. <i>Surgical Oncology</i> , 2008 , 17, 277-9	2.5	1
100	Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). <i>World Journal of Surgical Oncology</i> , 2008 , 6, 63	3.4	50
99	Melanoma adrenal metastasis: natural history and surgical management. <i>American Journal of Surgery</i> , 2008 , 195, 363-8; discussion 368-9	2.7	56
98	Human melanoma cytotoxicity by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. <i>Cancer Research</i> , 2008 , 68, 4392-7	10.1	34
97	A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. <i>Cancer Research</i> , 2008 , 68, 8419-28	10.1	60
96	Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4296-303	2.2	165
95	Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. <i>Clinical and Experimental Metastasis</i> , 2008 , 25, 191-9	4.7	14
94	Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. <i>Cancer</i> , 2008 , 112, 2030-7	6.4	19
93	Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. <i>Cancer</i> , 2008 , 112, 2249-57	6.4	60
92	Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. <i>Human Mutation</i> , 2008 , 29, 1443-51	4.7	46
91	Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. <i>International Journal of Cancer</i> , 2008 , 122, 2077-84	7.5	47
90	Radiation Treatment Field Delineation for Axillary Metastases from Malignant Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 72, S105-S106	4	2
89	How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? <i>Annals of Surgical Oncology</i> , 2008 , 15, 670-3	3.1	36
88	Staging and prognostic factors for stage IV melanoma: Initial results of an American Joint Committee on Cancer (AJCC) international evidence-based assessment of 4,895 melanoma patients. <i>Journal of Clinical Oncology</i> , 2008 , 26, 9035-9035	2.2	3
87	Sentinel Lymph Node Biopsy in Cutaneous Melanoma 2008 , 92-110		2
86	Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. <i>Cancer</i> , 2007 , 109, 1570-8	6.4	21

85	Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 387-93	4.3	42
84	Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 276-80	4.3	44
83	Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. <i>Annals of Surgical Oncology</i> , 2007 , 14, 2867-75	3.1	50
82	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. <i>Annals of Oncology</i> , 2007 , 18, 806-8	10.3	14
81	Is sentinel-node biopsy superior to nodal observation in melanoma?. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 278-9		13
80	Cost effectiveness of adjuvant interferon in node-positive melanoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2442-8	2.2	23
79	Imaging studies in patients with melanoma. <i>Surgical Oncology Clinics of North America</i> , 2007 , 16, 403-30	2.7	35
78	HLA class II alleles predict recurrence and pattern of failure in early-stage melanoma patients. <i>Journal of Clinical Oncology</i> , 2007 , 25, 8503-8503	2.2	
77	Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. <i>Cancer</i> , 2006 , 106, 900-6	6.4	89
76	Metastatic melanoma to lymph nodes in patients with unknown primary sites. <i>Cancer</i> , 2006 , 106, 2012-20.4	6.4	88
75	Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. <i>Cancer</i> , 2006 , 107, 2647-52	6.4	75
74	Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. <i>JAMA Otolaryngology</i> , 2006 , 132, 370-3		84
73	Ethnic differences among patients with cutaneous melanoma. <i>Archives of Internal Medicine</i> , 2006 , 166, 1907-14		195
72	Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. <i>American Journal of Roentgenology</i> , 2006 , 187, W117-9	5.4	7
71	Activation of stat3 in human melanoma promotes brain metastasis. <i>Cancer Research</i> , 2006 , 66, 3188-96	10.1	330
70	Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 2526-32	4	73
69	Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2858-65	2.2	75
68	Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. <i>Neoplasia</i> , 2006 , 8, 747-57	6.4	23

67	Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. <i>Annals of Surgical Oncology</i> , 2006 , 13, 712-20	3.1	116
66	Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. <i>Carcinogenesis</i> , 2006 , 27, 1894-901	4.6	72
65	Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 253-63	1.9	39
64	Combined-modality therapy for patients with regional nodal metastases from melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 64, 106-13	4	65
63	Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. <i>Clinical Cancer Research</i> , 2006 , 12, 6709-15	12.9	79
62	Invasive squamous cell carcinoma of the skin: defining a high-risk group. <i>Annals of Surgical Oncology</i> , 2006 , 13, 902-9	3.1	149
61	Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. <i>Annals of Surgical Oncology</i> , 2006 , 13, 809-16	3.1	130
60	Structure function relationships in the lymphatic system and implications for cancer biology. <i>Cancer and Metastasis Reviews</i> , 2006 , 25, 159-84	9.6	95
59	Microscopic tumor burden in sentinel lymph nodes (SLNs) best predicts nonsentinel lymph node (NSLN) involvement in patients with melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 8004-8004	2.2	3
58	The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4588-90	2.2	97
57	Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. <i>European Journal of Surgical Oncology</i> , 2005 , 31, 323-4	3.6	7
56	Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2005 , 12, 587-96	3.1	167
55	Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. <i>Journal of the American College of Surgeons</i> , 2005 , 201, 821-3; author reply 823-4	4.4	28
54	Management of early-stage cutaneous melanoma. <i>Current Problems in Surgery</i> , 2005 , 42, 460-534	2.8	2
53	In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1822-31	9.7	44
52	Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. <i>Cancer Research</i> , 2005 , 65, 11185-92	10.1	62
51	Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6054-62	2.2	78
50	Gene expression profiling of human cutaneous melanoma: are we there yet?. <i>Cancer Biology and Therapy</i> , 2004 , 3, 121-3	4.6	9

49	The new staging system for cutaneous melanoma in the era of lymphatic mapping. <i>Seminars in Oncology</i> , 2004 , 31, 415-25	5.5	8
48	An evidence-based staging system for cutaneous melanoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2004 , 54, 131-49; quiz 182-4	220.7	270
47	Lymphatic mapping in the molecular era. <i>Annals of Surgical Oncology</i> , 2004 , 11, 362-74	3.1	22
46	A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. <i>Annals of Surgical Oncology</i> , 2004 , 11, 1079-84	3.1	55
45	Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. <i>Cancer</i> , 2004 , 100, 383-9	6.4	59
44	Contralateral prophylactic mastectomy. Predictors of significant histologic findings. <i>Cancer</i> , 2004 , 101, 1977-86	6.4	92
43	Lessons learned from the Sunbelt Melanoma Trial. <i>Journal of Surgical Oncology</i> , 2004 , 86, 212-23	2.8	179
42	Adverse events associated with the intraoperative injection of isosulfan blue. <i>Journal of Clinical Anesthesia</i> , 2004 , 16, 332-41	1.9	21
41	Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 308-15	9.7	129
40	Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. <i>Melanoma Research</i> , 2003 , 13, 379-87	3.3	24
39	Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. <i>Annals of Surgical Oncology</i> , 2003 , 10, 348-54	3.1	44
38	Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. <i>Annals of Surgical Oncology</i> , 2003 , 10, 569-374	3.1	164
37	p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , 2003 , 121, 1510-4	4.3	39
36	New TNM melanoma staging system: linking biology and natural history to clinical outcomes. <i>Journal of Surgical Oncology</i> , 2003 , 21, 43-52		90
35	Surgical clinical trials in melanoma. <i>Surgical Clinics of North America</i> , 2003 , 83, 385-403	4	8
34	The new melanoma staging system. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2003 , 22, 42-54	1.4	22
33	Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. <i>Cancer</i> , 2002 , 95, 354-60	6.4	74
32	Adjuvant irradiation for axillary metastases from malignant melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 964-72	4	91

31	Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4555-8	2.2	117
30	Cancer. Targeting lymphatic metastasis. <i>Science</i> , 2002 , 296, 1811-2	33.3	45
29	Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3622-34	2.2	2077
28	Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3635-48	2.2	2173
27	Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. <i>Annals of Surgical Oncology</i> , 2001 , 8, 116-22	3.1	25
26	Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?. <i>Annals of Surgical Oncology</i> , 2001 , 8, 192-7	3.1	207
25	Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. <i>Annals of Surgical Oncology</i> , 2001 , 8, 766-70	3.1	98
24	Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. <i>Oncogene</i> , 2001 , 20, 3363-75	9.2	68
23	Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2851-5	2.2	180
22	Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes 2001 , 8, 116		1
21	A new American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Cancer</i> , 2000 , 88, 1484-91	6.4	331
20	Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. <i>Annals of Surgical Oncology</i> , 2000 , 7, 226-31	3.1	49
19	Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. <i>Annals of Surgical Oncology</i> , 2000 , 7, 160-5	3.1	200
18	Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. <i>Annals of Surgical Oncology</i> , 2000 , 7, 256-61	3.1	66
17	How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?. <i>Surgery</i> , 2000 , 128, 306-11	3.6	36
16	Clinical classification and staging. <i>Clinics in Plastic Surgery</i> , 2000 , 27, 361-76, viii	3	6
15	Classification and staging of melanoma. <i>Clinics in Laboratory Medicine</i> , 2000 , 20, 785-815	2.1	6
14	Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. <i>Journal of Clinical Oncology</i> , 1999 , 17, 976-83	2.2	1039

13	Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. <i>Annals of Surgical Oncology</i> , 1998 , 5, 322-8	3.1	164
12	Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. <i>Annals of Surgical Oncology</i> , 1998 , 5, 529-38	3.1	28
11	Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. <i>Surgery</i> , 1998 , 124, 203-210	3.6	168
10	Classification and staging of melanoma. <i>Hematology/Oncology Clinics of North America</i> , 1998 , 12, 737-65	3.1	28
9	Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. <i>Journal of Biological Chemistry</i> , 1998 , 273, 16501-8	5.4	120
8	Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2253-60	2.2	478
7	Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. <i>Surgery</i> , 1998 , 124, 203-10	3.6	33
6	Prognostic significance of the sentinel lymph node (SLN) in stage I or II melanoma patients. <i>Melanoma Research</i> , 1997 , 7, S105	3.3	6
5	Nodal failure after lymphatic mapping (LM) and negative sentinel lymph node (SLN) biopsy in stage I or II melanoma patients. <i>Melanoma Research</i> , 1997 , 7, S29	3.3	2
4	Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. <i>American Journal of Pathology</i> , 1997 , 151, 1105-13	5.8	258
3	Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses. <i>Journal of Infectious Diseases</i> , 1992 , 165, 859-64	7	51
2	Interleukin 1 receptor blockade attenuates the host inflammatory response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 4966-70	11.5	177
1	Lymphatic Mapping and Sentinel Lymph Node Biopsy	501-515	